INDICATIONS:indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis
FDA APPROVAL DATE:07/27/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: None known
PREGNANCY: no available data
Risk of Death in Preterm Infants due to Pulmonary Lipid Accumulation; Hypersensitivity Reactions; Risk of Infections, Fat Overload Syndrome, Refeeding Syndrome, and Hypertriglyceridemia; Aluminum Toxicity
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.
